Market Research Blog

Global demand for loop-mediated isothermal amplification technology reached around US$ 85 million in 2018, as indicated by a new research study of Future Market Insights (FMI). Estimated to observe stable growth in revenue over the coming years, loop-mediated isothermal amplification market will witness dominance of DNA polymerase, among the various product types.

Get Sample of the Report : https://www.futuremarketinsights.com/reports/sample/rep-gb-5532

Dominance of DNA Polymerase Adoption to Prevail, LAMP Instruments to Emerge Lucrative

DNA polymerase will continue to find highest applicability in both research and diagnostics. According to FMI’s report, DNA polymerase will be the key revenue generating product in loop-mediated isothermal amplification market over the period of projection. However, the report also highlights that instruments such as turbidimeters and fluorescence measuring systems will prominent traction in loop-mediated isothermal amplification market through 2028.

Amongst various loop-mediated isothermal amplification technologies, micro-fluidic technology majorly, have been successfully used in the diagnosis of several diseases including malaria and tuberculosis. Loop-mediated isothermal amplification using DNA polymerase has seen a rapid rise in the past several years due to the high adoption of loop-mediated isothermal amplification in testing.

The application of these Loop-mediated isothermal amplification in assessing and directing diagnosis in certain types of disease, such as acute malaria, has provided a new dimension to the gradually growing field of minimal residual disease management.

High Penetration of Cutting-edge Technology Molecular Diagnostics of Fatal Diseases to Push LAMP Market Growth

The simplicity sensibility and specificity of loop-mediated isothermal amplification puts it in a very good position for future development in life threatening disease diagnosis. It is anticipated that the loop-mediated isothermal amplification market will grow significantly during the forecast period, owing mainly due to demand for advanced molecular diagnostics to accurately diagnose life-threatening diseases.

In recent years, the detection and identification of nucleic acids using point-of-care total nucleic acid analysis systems and procedures are in rise including loop-mediated isothermal amplification in various clinical and industrial settings. Besides loop-mediated isothermal amplification has also challenged PCR based amplification as it could achieve enhanced nucleic acid amplification by increasing surface area to volume ratio with reduced testing cost.

Macroeconomic indicators such as government funding for advancement and increased research on disease epigenetics; establishment of network of distribution and marketing agreements to ensure availability of products to different loop-mediated isothermal amplification end users globally; liberalization of import and export trade on point of care diagnostic devices and chemical reagents are also anticipated to propel the growth of the loop-mediated isothermal amplification market.

Purchase the Report : https://www.futuremarketinsights.com/checkout/5532

Key Challenges Facing Development of Loop-mediated Isothermal Amplification Market

On the grey side, loop-mediated isothermal amplification has several intrinsic disadvantages such as its amplification method is devoid of an internal PCR inhibition control (IC). It is essential to perform all the reactions in duplicate, one being or the target and the other one for the IC in loop-mediated isothermal amplification assay.

Moreover, most standard DNA polymerases are unable to exhibit activity in samples derived from crude lysate due to the presence of polymerase inhibitors. This adds complexity to the loop-mediated isothermal amplification processing due to additional steps involved in purifying DNA to be used for amplification, which could also result in loss of starting material.

Regions with High Disease Prevalence to Reflect High Growth Potential for LAMP Market

Due to increase in prevalence of malaria and other pandemic diseases, regions such as East and South Asia are anticipated to be the fastest growing regional loop-mediated isothermal amplification markets and are poised to offer tremendous opportunities to key players. The increase in disease prevalence will increase the demand for the use of loop-mediated isothermal amplification for point-of-care diagnosis. Besides, distribution & collaboration agreements by leading players of loop-mediated isothermal amplification products with the established local distributors in the regions will fuel the market growth of both the regions.

The loop-mediated isothermal amplification market report tracks some of the key companies operating in the global loop-mediated isothermal amplification market such as Eiken Chemcial Co., Ltd, New England Biolabs, Jena Bioscience GmbH, NIPPON GENE CO., LTD, HUMAN, Optigene, HiberGene Diagnostics, Meridian Bioscience, Inc., and Mast Group Ltd among others.

According to the latest research by the FMI, the global urology imaging systems market is expected to account for over US$ 486.4 Mn, in terms of value, by 2028 end. The report on the Urology Imaging Systems market further projects substantial growth potential with CAGR of 3.7% over 2022-2028.

While hospitals will continue to register the highest revenue share in terms of urology imaging systems adoption, the report highlights limited investment opportunities for manufacturers of urology imaging systems, within clinics.

Get Sample of the Report : https://www.futuremarketinsights.com/reports/sample/rep-gb-8911

Increasing EU Reserve Funding Encouraging Adoption of Urology Imaging Systems

Increasing instances of urological disease and simultaneously increasing awareness about critical health issues is anticipated to boost demand for urology imaging systems and services across globe. Accessibility of EU reserves for part states in the CEE, paralleled by administrative projects in Russia, will be an imperative source of financing for new imaging equipment purchases and will contribute fundamentally to the advancement of the urology imaging systems market in the Eastern Europe.

In Russia, the 2020 Healthcare Development Program and National Project ‘Health’ center not just around conveying propelled advances to the nation and furnishing healthcare facilities with costly, top of the line urology imaging systems, yet additionally on obtaining mid-range and low-end urology imaging systems that are very required in local health facilities. The compliance to the EU reserve funding has given access to countries like the Czech Republic, Hungary, Poland, Bulgaria and Romania. Such compliances are anticipated to eliminate barriers for the new entrant in urology imaging systems market.

The growing demand for urology imaging systems is centered at increasing inclination towards technologically-advanced imaging tools used in the diagnosis of prostate cancer and uterine fibroid to reduce the risk of uterine cancer. Further increasing demand for urology imaging systems for accurate diagnosis and second opinion is anticipated to create demand for ultrasound- as well as fluoroscopy-based urology imaging systems, thereby driving the growth of the Urology Imaging Systems market. However, ultrasound systems are likely to continue representing a larger market value share over fluoroscopic variants, according to FMI’s analysis.

Favorable Reimbursement Scenario, Supported by Increasing Number of Diagnostic Establishments Driving Market Growth

In the recent years, the number of independent diagnostics and imaging centers in various developed and developing regions has seen a significant spike, overcoming a series of volume and reimbursement pressures in an effort to sustain profitability and achieve better margins. This according to the report is expected to drive the growth of the Urology Imaging Systems market.

Many insurance companies have adopted effective marketing strategies to shift the patient volume to low-cost independent diagnostic centers and reduce the price point associated with urology imaging systems. Independent diagnostic imaging centers offer better service and often of superior quality, generally at the expense of local hospitals and weak operators. The development of low cost portable urology imaging systems is providing leverage to current imagining centers and subsequently driving the growth of Urology Imaging Systems market.

Purchase the Report : https://www.futuremarketinsights.com/checkout/8911

The report tracks strategic developments of some of the prominent players competing in  the global urology imaging systems market, including GE Healthcare, Toshiba Medical, Philips Healthcare, Hitachi-Aloka Medical, Siemens Healthineers, Samsung Medison, Mindray, Fujifilm Sonosite, Esaote, and Analogic. The report also provides key aspects and trends in the Urology Imaging Systems market, including reimbursement scenario, average selling price, and country-wise revenue analysis.

The hematology diagnostics market has witnessed the advent of a wide range of hematology testing solutions that combine the attributes of strainer, slider maker, and cell counter. Integrated solutions have been gaining ground in the hematology diagnostics market, as growing work load has prompted pathologists to adopt methods with precision and accuracy for improved results.

According to a recent study of Future Market Insights (FMI), the hematology diagnostics market recorded a valuation of approximately US$ 3,500 Mn in 2017. Growing popularity of modern day analyzers that offer five to seven parts white cell differential analysis, along with additional information on cell population data (CPD), large unstained cell population, and granularity index, will continue to drive growth of the hematology diagnostics market.

Get Sample of the Report : https://www.futuremarketinsights.com/reports/sample/rep-gb-9046

The study opines that the hematology diagnostics market will continue to remain a consolidated landscape, with few established players collectively accounting for a larger share of the market. Robust portfolio, and stronger distribution footprint of these leading players, including F. Hoffmann-La Roche Ltd., Beckman Coulter, Inc., Abbott Laboratories, and Sysmex Corporation, will continue to uphold their lead in the hematology diagnostics market in the upcoming years.

Key players in the hematology diagnostics market are focusing on strategic partnerships with vendors having innovative technologies, to gain a greater share with more diverse portfolios. Other leading players profiled in the report on the hematology diagnostics market include HORIBA, Ltd., HemoCue AB, Mindray Medical International Limited, Danaher (Beckman Coulter, Inc.), Bio-Rad Laboratories, Inc., and Siemens Healthineers.

Emphasis on Effective Hematology Diagnostics to Surge in Line with Prevalence of Blood Cancer

There has been a marked rise in the prevalence of blood disorders, and the pervasiveness of these ailments will continue to surge in the foreseeable future, according to the report. This has further driven the essentiality of hematology diagnostics with greater efficacy, thereby complementing new product developments and technological advancements in the hematology diagnostics market worldwide.

Recent studies from associated regulatory authorities estimated that, in the US alone, number of individuals affected with blood-related disorders reached nearly 173,000 in 2017. This has further led the healthcare institutes and governments to take up initiatives for increasing awareness of these disorders and the availability of related management & treatment procedures, which in turn has led the demand and adoption of hematology diagnostics in the recent past.

Point-of-care testing has also witnessed a notable rise in demand, with technological advancements leading to results with higher accuracy and convenience. Easy availability of myriad test methods for hematology diagnostics has also been a key factor driving growth of the market. The study estimates that the hematology diagnostics market

Purchase the Report : https://www.futuremarketinsights.com/checkout/9046

Gains from Hematology Diagnostics Market in Developed Markets to Remain Higher

The study anticipated Europe and North America to remain the most lucrative markets for the hematology diagnostics market. Relatively greater prevalence of blood-related disorders, higher awareness about the existing screening techniques for blood disorders, and rising expenditure on health & wellness by consumers, allude greater gains from the hematology diagnostics market in Europe and North America.

Sensing varied requirements of the healthcare settings and the distinctions in the blood ailments, key players in the hematology diagnostics market have introduced a wide range of hematology instruments, According to the study, hematology analyzers currently accounts for the largest share in the hematology diagnostics market.

This FMI report also offers an accurate forecast of the hematology diagnostics market for the period between 2018 and 2026. The hematology diagnostics market is envisaged to record a CAGR of over 5% through 2026. 

In its new study, Future Market Insights (FMI) has forecast the global allergy immunotherapy market to register healthy growth between 2020 and 2030. The study also projects that market will reach a valuation of US$ 2,892.2 Mn by the end of 2030

The increasing prevalence of various kinds of allergies – allergic rhinitis, allergic asthma, food allergies, skin allergies, and others is propelling the demand for effective treatments. As patients seek advanced treatments to develop resistance against allergies and lead a hassle-free life, allergy immunotherapy has emerged as a fitting medical solution.

Get Sample of the Report : https://www.futuremarketinsights.com/reports/sample/rep-gb-9043

Moreover, allergic rhinitis is among the most common allergies, affecting 10% to 30% of the global population. Also known as hay fever, it leads to inflammation in the nose, swelling in the eyes, sneezing, among other symptoms when the person is exposed to allergens – mostly dust mites and pollen.

Although a remarkable proportion of the population does not seek medical attention, rising awareness regarding the availability of these treatments, coupled with increased spending on healthcare is expected to remain a crucial demand-side trend through the forecast period.

Key Takeaways from the Allergy Immunotherapy Study

• On the basis of product, injections are poised to account for over 2/3rds of market share backed by their effectiveness and easy availability
• Based on immunotherapy, SCIT holds the lion’s share in market value, accounting for 66% of global value, while SLIT is exhibiting higher attractiveness
• Among indications, allergic rhinitis and allergic asthma are poised to collectively account for around 3/5th of global value, ascribed to their high prevalence
• By type of allergen, pollens and house dust mites will cumulatively account for more than 2/5th of market value since pollens such as grass pollen and weed pollen are highly common in living areas
• Based on distribution channels, institutional sales account for more than half of overall value owing to high inpatient rates in government and semi-government hospitals
• Europe is expected to prevail as the most lucrative regional market, on the back of the rising prevalence of different types of allergies in the region
• North America and East Asia will cumulatively account for more than a quarter of market value, owing to the presence of a wide population base with allergies coupled with developing healthcare infrastructure

“Market players are focusing on developing novel treatment methodologies and procuring approvals from concerned authorities to strengthen their foothold,” said a FMI analyst.

COVID-19 Impact on Allergy Immunotherapy Market

The outbreak of COVID-19 has sent ripples of uncertainty across the global pharmaceutical sector and the allergy immunotherapy market is no different. The market is expected to witness several mid-term and long-term impacts due to the pandemic, as demand for SLIT tablets and injections experiences contraction. Likewise, shifting presence towards essential drugs is causing a delay in services, thus further slowing down the growth of the market. Along similar lines, shortages of staff and hindered supply chains during nation-wide lockdowns will further challenge the growth through the pandemic.

Purchase the Report : https://www.futuremarketinsights.com/checkout/9043

Who is Winning?

Key players operating in the market are directing their efforts towards developing novel products and obtaining approvals to ensure revenue prospects and maintain their foothold amid the competition. On these lines:

• In May 2020, Stallergenes Greer announced the expansion of the supply of subcutaneous products (SCIT), to expand its offering to patients suffering from asthma, who are at a higher risk of COVID-19.
• In April 2020, ALK Abello announced that Health Canada has approved once-daily ITULATEK, a sublingual tablet for the treatment of tree pollen allergy.

FMI’s report includes profiles of some of the most prominent names in the market including ALK Abello (Europe), Stallergenes Greer (Europe), Allergy Therapeutics (Europe), Aimmune Therapeutics (U.S.), Anergis (Europe), Arrayit Corporation (U.S.), Biomay AG (Europe), HAL Allergy Group (Europe), DBV Technologies (Europe), and others.

The approximately US$ 25 Bn market for benign prostatic hyperplasia prostate treatment is likely to expand at 4.6% CAGR during 2018-2028, according to a recent research report of Future Market Insights (FMI). The report has envisaged steady growth prospects for the revenue of global benign prostatic hyperplasia prostate treatment market through 2028.

The World Population Prospects’ data (2017) projected that the number of individuals aged 60 years and above will double by 2050, and triple by 2100. With such a high pace estimated for the growth of population aged 60 years and above, it is more likely that the prevalence of aging related health conditions will also increase at a considerable pace in the years to come. A high prevalence rate of benign prostatic hyperplasia (BPH) in men, the demand for improved and more effective treatment options continues to increase at a high rate.

Get Sample of the Report : https://www.futuremarketinsights.com/reports/sample/rep-gb-1664

Alpha-blockers & Drugs for Lower UTIs Remain Pivotal in Benign Prostatic Hyperplasia Prostate Treatment

The drug treatment has been vital in treating benign prostatic hyperplasia conditions and lower UTIs, which has been attributed to widespread availability of drug-based benign prostatic hyperplasia prostate treatment. This factor, in particular, will play an instrumental role in driving the growth of the benign prostatic hyperplasia prostate treatment market during the forecast period. Drugs will remain the first choice of treatment for benign prostatic hyperplasia.

Benign prostatic hyperplasia increases the risk of other disorders as well. The most common disorder caused due to benign prostatic hyperplasia is lower UTI (urinary tract infection) for which, Alpha-blockers constitute the first line of treatment. However, other drugs are also available in the market, which offer relief from the benign prostatic hyperplasia symptoms. Other drugs include alpha reductase inhibitors, phosphodiesterase-5 (PDE-5) inhibitors, muscarinic receptor antagonists, and combination drugs.

Demand for Benign Prostatic Hyperplasia Prostate Treatment Higher in Developed Regions, Patient Pool Expanding Steadily in Developing Markets

Owing to significantly growing prevalence of benign prostatic hyperplasia in North American men, benign prostatic hyperplasia prostate treatment market is expected to witness strong growth within the region, followed by Europe.

Extensive availability of benign prostatic hyperplasia prostate treatments, increasing clinical trials, improving R&D scenario, higher healthcare spending, and favorable government initiatives will continue to assist the growth of the benign prostatic hyperplasia prostate treatment market in developed regions.

On the other side, Asia Pacific’s benign prostatic hyperplasia prostate treatment market is foreseen to witness significant growth, owing to steadily expanding patient pool due in the region.

UroLift System to Revolutionize the Competitive Landscape of Benign Prostatic Hyperplasia Prostate Treatment Market

Teleflex Incorporated’s NeoTract recently launched UroLift® System as a highly effective, least invasive option for benign prostatic hyperplasia prostate treatment. The UroLift® System is permanently implanted via a transurethral outpatient procedure and predominantly relieves prostate obstruction, which is one of the primary symptoms of benign prostatic hyperplasia. The company has also declared insurance coverage for UroLift® System. While the coverage is being provided by Humana, it is most likely to improve awareness about increasing availability and broadening access of minimally invasive treatment methods in urological conditions such as benign prostatic hyperplasia. This in turn will encourage adoption of UroLift® System among patients seeking effective benign prostatic hyperplasia prostate treatment.

Purchase the Report : https://www.futuremarketinsights.com/checkout/1664

A majority of patients with enlarged prostate continue to perceive medication and surgery as the only available treatment alternatives. However, an increasing number of physician recommendations is advocating the use of The UroLift® System as it eliminates side effects associated with other conventional options of benign prostatic hyperplasia prostate treatment.